The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Feb 5

PMID 33540932

Citations 6

Authors

Yimei Jia

Bassel Akache

Gerard Agbayani

Vandana Chandan

Renu Dudani

Blair A Harrison

Lise Deschatelets

Usha D Hemraz

Edmond Lam

Sophie Regnier

Felicity C Stark

Lakshmi Krishnan

Michael J McCluskie

Affiliations

Soon will be listed here.

Abstract

Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations.

Citing Articles

Sulfated lactosyl archaeol (SLA) archaeosomes as a vaccine adjuvant.

Akache B, McCluskie M Hum Vaccin Immunother. 2024; 20(1):2395081.

PMID: 39278862 PMC: 11404618. DOI: 10.1080/21645515.2024.2395081.

Development of semisynthetic saponin immunostimulants.

Bai D, Kim H, Wang P Med Chem Res. 2024; 33(8):1292-1306.

PMID: 39132259 PMC: 11315725. DOI: 10.1007/s00044-024-03227-x.

Poly(I:C) and R848 ligands show better adjuvanticity to induce B and T cell responses against the antigen(s).

Tandel N, Patel D, Thakkar M, Shah J, Tyagi R, Dalai S Heliyon. 2024; 10(5):e26887.

PMID: 38455541 PMC: 10918150. DOI: 10.1016/j.heliyon.2024.e26887.

Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Akache B, Stark F, Agbayani G, Renner T, McCluskie M Methods Mol Biol. 2021; 2412:179-231.

PMID: 34918246 DOI: 10.1007/978-1-0716-1892-9_9.

Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.

Akache B, Renner T, Tran A, Deschatelets L, Dudani R, Harrison B Sci Rep. 2021; 11(1):21849.

PMID: 34750472 PMC: 8576046. DOI: 10.1038/s41598-021-01363-7.

References

Stark F, Agbayani G, Sandhu J, Akache B, McPherson C, Deschatelets L . Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma. Biomedicines. 2019; 7(4). PMC: 6966619. DOI: 10.3390/biomedicines7040091. View

Akache B, Stark F, Jia Y, Deschatelets L, Dudani R, Harrison B . Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice. PLoS One. 2018; 13(12):e0208067. PMC: 6279041. DOI: 10.1371/journal.pone.0208067. View

Garcon N, Di Pasquale A . From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother. 2016; 13(1):19-33. PMC: 5287309. DOI: 10.1080/21645515.2016.1225635. View

Akache B, Deschatelets L, Harrison B, Dudani R, Stark F, Jia Y . Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins. Vaccines (Basel). 2019; 7(4). PMC: 6963754. DOI: 10.3390/vaccines7040204. View

Jia Y, Akache B, Deschatelets L, Qian H, Dudani R, Harrison B . A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations. Int J Pharm. 2019; 561:187-196. DOI: 10.1016/j.ijpharm.2019.02.041. View

Agbayani G, Jia Y, Akache B, Chandan V, Iqbal U, Stark F . Mechanistic insight into the induction of cellular immune responses by encapsulated and admixed archaeosome-based vaccine formulations. Hum Vaccin Immunother. 2020; 16(9):2183-2195. PMC: 7553676. DOI: 10.1080/21645515.2020.1788300. View

Haq K, Jia Y, Krishnan L . Archaeal lipid vaccine adjuvants for induction of cell-mediated immunity. Expert Rev Vaccines. 2016; 15(12):1557-1566. DOI: 10.1080/14760584.2016.1195265. View

Stark F, Akache B, Ponce A, Dudani R, Deschatelets L, Jia Y . Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization. Vaccine. 2019; 37(47):7108-7116. DOI: 10.1016/j.vaccine.2019.07.010. View

Makinen S, Zhu Q, Davis H, Weeratna R . CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE). Int Immunol. 2016; 28(9):453-61. DOI: 10.1093/intimm/dxw017. View

10.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

11.

Akache B, Stark F, Iqbal U, Chen W, Jia Y, Krishnan L . Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants. Hum Vaccin Immunother. 2018; 14(7):1746-1759. PMC: 6067861. DOI: 10.1080/21645515.2017.1423154. View

12.

Ansari M, Zubair S, Mahmood A, Gupta P, Khan A, Gupta U . RD antigen based nanovaccine imparts long term protection by inducing memory response against experimental murine tuberculosis. PLoS One. 2011; 6(8):e22889. PMC: 3154911. DOI: 10.1371/journal.pone.0022889. View

13.

Bonam S, Partidos C, Halmuthur S, Muller S . An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy. Trends Pharmacol Sci. 2017; 38(9):771-793. DOI: 10.1016/j.tips.2017.06.002. View

14.

Higa L, Corral R, Morilla M, Romero E, Petray P . Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease. Hum Vaccin Immunother. 2013; 9(2):409-12. PMC: 3859765. DOI: 10.4161/hv.22780. View

15.

Barber D, Wherry E, Ahmed R . Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol. 2003; 171(1):27-31. DOI: 10.4049/jimmunol.171.1.27. View

16.

Weeratna R, McCluskie M, Xu Y, Davis H . CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 2000; 18(17):1755-62. DOI: 10.1016/s0264-410x(99)00526-5. View

17.

Haq K, Jia Y, Elahi S, Maclean S, Akache B, Gurnani K . Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen. Vaccine. 2019; 37(47):7029-7040. DOI: 10.1016/j.vaccine.2019.08.079. View

18.

Fitzgerald K, Kagan J . Toll-like Receptors and the Control of Immunity. Cell. 2020; 180(6):1044-1066. PMC: 9358771. DOI: 10.1016/j.cell.2020.02.041. View

19.

Davis H, Weeratna R, Waldschmidt T, Tygrett L, Schorr J, Krieg A . CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998; 160(2):870-6. View

20.

Ansari M, Zubair S, Tufail S, Ahmad E, Khan M, Quadri Z . Ether lipid vesicle-based antigens impart protection against experimental listeriosis. Int J Nanomedicine. 2012; 7:2433-47. PMC: 3383290. DOI: 10.2147/IJN.S25875. View